CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
CEL SCI CORP
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.14 (-7.82%)
Close on Oct 19, 2026
- Market cap
- $19.99M
- P/E (TTM)
- –
- Dividend yield
- –
Cel Sci statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Cel Sci | Industry median |
|---|---|---|
| Market Cap | $29.02M | $166.30M |
| Enterprise Value | $22.49M | $88.19M |
| PB Ratio | 2.65 | 2.03 |
| P/TBV Ratio | 2.67 | 2.29 |
Income (trailing twelve months)
| Measure | Cel Sci | Industry median |
|---|---|---|
| Operating Income | -$22.29M | -$21.40M |
| Net Income | -$22.70M | -$22.46M |
| EBITDA | -$20.29M | -$16.91M |
Returns
| Measure | Cel Sci | Industry median |
|---|---|---|
| Return on Equity (ROE) | -252.5% | -53.2% |
| Return on Assets (ROA) | -108.9% | -40.9% |
| Return on Invested Capital (ROIC) | -364.5% | -32.4% |
| Return on Capital Employed (ROCE) | -136.9% | -38.1% |
Balance sheet
| Measure | Cel Sci | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.53M | $61.43M |
| Net Cash (Debt) | $6.53M | $15.35M |
| Net Cash Per Share | $0.37 | $0.66 |
| Equity (Book Value) | $10.96M | $49.09M |
| Book Value Per Share | $0.62 | $1.37 |
| Tangible Book Value | $10.89M | $23.52M |
| Working Capital | $2.42M | $76.81M |
Financial position
| Measure | Cel Sci | Industry median |
|---|---|---|
| Current Ratio | 1.48 | 3.34 |
| Quick Ratio | 1.28 | 2.44 |
| Interest Coverage | -50.08 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Cel Sci | Industry median |
|---|---|---|
| Operating Cash Flow | -$16.75M | -$12.35M |
| Capital Expenditures | -$5.16K | -$1.08M |
| Free Cash Flow | -$16.75M | -$20.22M |
| FCF Per Share | -$0.95 | -$0.42 |
Efficiency
| Measure | Cel Sci | Industry median |
|---|---|---|
| Profits Per Employee | -$338.86K | -$703.34K |
| Employee Count | 67 | 74 |
Dividends and yields
| Measure | Cel Sci | Industry median |
|---|---|---|
| Earnings Yield | -78.2% | -23.3% |
| FCF Yield | -57.7% | -8.72% |
| Buyback Yield | -87.6% | -0.59% |
| Shareholder Yield | -87.6% | 0.00% |
Shares
| Measure | Cel Sci | Industry median |
|---|---|---|
| Shares Outstanding | 17,589,000 | 58,127,000 |
| Shares Change (YoY) | 215.5% | 10.9% |
| Shares Change (QoQ) | 107.1% | 0.54% |
| Float | 16,861,700 | 49,136,700 |
| Shares Held by Insiders | 4.14% | 11.6% |
| Shares Held by Institutions | 11.3% | 59.4% |
Scores
| Measure | Cel Sci | Industry median |
|---|---|---|
| Altman Z-Score | -38.08 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Cel Sci's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.